Synta Pharmaceuticals (SNTA) Announces Publications Demonstrating Ganetespib Activity In Triple-Negative Breast Cancer Models
11/22/2013 8:58:38 AM
LEXINGTON, Mass.--(BUSINESS WIRE)--Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced two publications with results demonstrating the activity of ganetespib in preclinical models and in a clinical treatment setting of triple-negative breast cancer (TNBC). Ganetespib is a potent and selective inhibitor of the Hsp90 chaperone protein being evaluated in over 25 clinical trials, including a pivotal Phase 3 trial in non-small cell lung cancer.
Help employers find you! Check out all the jobs and post your resume.
comments powered by